i don't take the safety in Singapore and Dubai for granted.if you're living in the 3rd world and you've made a bag off crypto profits, maybe reconsider the Rolex purchase.Instead: maybe get an Omega, Vacheron Constantin or Jaeger Lecoultre? https://t.co/36JuYjyiuP ...

高纯度 Omega-3丨 白皮书 核心摘要： 在健康中国战略全面推进的背景下，国民健康管理意识显著提升，健康需求从 "被动治疗"向"主动预防"加 速转型。随着慢性病防控与亚健康改善成为全民健康的核心议题，膳食营养补充剂已成为全民健康管理的重 要工具，其市场发展与科学认知深化同步推进。基于这一现状，本白皮书旨在深入探讨高纯度 Omega-3 在中国居民健康管理中的作用及应用现状，加强公众对其生理功效的认知，为公众提供更加专业的营养指 导。白皮书从以下五个章节展开： 一、中国居民健康管理现状 国家政策推动全民健康管理向主动预防转型，面对慢性病年轻化与全周期防护挑战，需构建监测、干预与营 养支持体系。膳食营养补充剂通过定向支持和免疫力提升，成为公众践行主动健康管理的核心工具，助力实 现从治疗到预防的跨越。 二、膳食营养补充剂市场认知及应用表现 在国民健康管理需求升级与膳食营养补充剂市场快速发展的双轮驱动下，服用膳食营养补充剂已进阶为现代 人健康管理的核心方案。在消费者决策矩阵中，产品本身与品牌背书构成购买双引擎。但不同人群对成分需 求呈现差异化特征，折射精准健康管理趋势。 三、 Omega-3 产品与应用现状 Om ...

Core Viewpoint - Moderna has experienced a significant decline in stock performance and sales due to waning demand for its coronavirus vaccine, losing over 90% of its value since its peak in 2021 [1][2][7] Company Background - Moderna initially gained prominence during the pandemic, generating up to $18.4 billion in annual revenue from its coronavirus vaccine, leading to substantial profits [4] - The company has since faced challenges as vaccine demand decreased, and its RSV vaccine sales have also underperformed [5] Cost Management and R&D Focus - In response to declining sales, Moderna has initiated a cost realignment plan aiming to reduce GAAP operating costs by up to $1.7 billion by 2027 [6] - The company is prioritizing research and development, with plans to launch as many as 10 new products in the next three years, although these launches are not guaranteed [6] Future Product Pipeline - Moderna anticipates having around 10 products on the market in 10 years, including several cancer vaccines and a cytomegalovirus vaccine, along with potential respiratory virus vaccines [11] - The company has a strong success rate in late-stage trials, with an 83% probability of success in phase 3 trials compared to the industry average of 69% [12] Revenue Projections - By 2028, Moderna expects to break even on an operating cash cost basis and generate $6 billion in revenue, with new product launches from 2026 to 2028 projected to yield a compounded annual growth rate of 25% or more [12] - Even with partial success in product launches, Moderna could achieve significant revenue growth over the next decade [13]

Core Insights - The article highlights the emergence of various health platforms, with YanJia platform standing out due to its unique positioning and professional services, becoming a trusted health management partner for consumers [1] Group 1: Professional Analysis of YanJia Platform - YanJia platform is part of XiRui Group, which has over ten years of experience in the health industry, providing a solid professional foundation for the platform [3] Group 2: Professional Health Consultant Team - The health consultants at YanJia platform are highly qualified professionals with strong backgrounds in nutrition and extensive practical experience, enabling them to tailor personalized health management plans for users [4] - The platform emphasizes one-on-one continuous service, ensuring that health consultants accompany users throughout their health management journey, providing care and respect [4] Group 3: Diverse Health Services - YanJia platform offers a wide range of services, including nutritional supplementation, immune system enhancement for children, gastrointestinal care, adolescent growth guidance, adult sub-health adjustment, and chronic disease prevention and management for the elderly [5] Group 4: Strict Selection of Quality Health Products - The platform carefully selects high-quality health products from around the world, ensuring that both international brands and domestic products meet stringent quality standards [6] - Examples of popular products include Brinowel Coenzyme Q10, known for its cardiovascular health benefits, and iNoromega classic seal oil, which also supports heart health [7] Group 5: Anniversary Celebration and Promotions - To celebrate its anniversary, YanJia platform has prepared a series of attractive promotional activities for users [9] - Specific promotions include discounts and gifts for purchasing certain quantities of products from brands like Brinowel and iNoromega, as well as daily coupon giveaways during the anniversary period [10][11] Group 6: Consumer Praise and Health Success Stories - YanJia platform has received high recognition and praise from consumers for its professional services and quality products [13] - Success stories include improved sleep quality and enhanced energy levels for users who followed personalized health plans provided by the platform's consultants [14][15] Group 7: Conclusion - YanJia platform, with its professional services, quality products, and generous anniversary promotions, is positioned as a reliable partner for consumers seeking to improve their health and quality of life [17]

Core Insights - Corbion has joined the Ferment4Health project, a public-private initiative led by Wageningen University, aimed at exploring the health benefits of fermented foods and postbiotics for gut health and chronic inflammation reduction [1][4] - The project seeks to validate the health claims associated with fermented foods like yogurt and kimchi through advanced research and real-world applications [2][4] - Corbion will leverage its expertise in fermentation and sustainable food solutions to develop next-generation functional food products based on scientific findings [3][4] Company Overview - Corbion is a sustainable ingredients company specializing in lactic acid, food preservation solutions, and algae ingredients, with a focus on health and sustainability [5][6] - In 2024, Corbion reported annual sales of €1,332.0 million and employed 2,399 full-time equivalents [6] - The company is listed on Euronext Amsterdam and aims to differentiate its products across various markets, including food, pharmaceuticals, and bioplastics [5][6] Project Details - The Ferment4Health project is co-funded by the Dutch Top Sector Agri & Food and Top Sector Life Sciences & Health, involving partners such as Kerry and Medex [4] - The consortium will utilize a multidisciplinary approach, including in vitro cell models and human clinical trials, to assess the impact of fermented products on intestinal health [4] - The initiative aims to connect academic research with industrial innovation to promote knowledge-driven product development in response to consumer interest in gut health [4]

高纯度 Omega-3丨 白皮书 核心摘要： 在健康中国战略全面推进的背景下，国民健康管理意识显著提升，健康需求从 "被动治疗"向"主动预防"加 速转型。随着慢性病防控与亚健康改善成为全民健康的核心议题，膳食营养补充剂已成为全民健康管理的重 要工具，其市场发展与科学认知深化同步推进。基于这一现状，本白皮书旨在深入探讨高纯度 Omega-3 在中国居民健康管理中的作用及应用现状，加强公众对其生理功效的认知，为公众提供更加专业的营养指 导。白皮书从以下五个章节展开： 一、中国居民健康管理现状 国家政策推动全民健康管理向主动预防转型，面对慢性病年轻化与全周期防护挑战，需构建监测、干预与营 养支持体系。膳食营养补充剂通过定向支持和免疫力提升，成为公众践行主动健康管理的核心工具，助力实 现从治疗到预防的跨越。 二、膳食营养补充剂市场认知及应用表现 在国民健康管理需求升级与膳食营养补充剂市场快速发展的双轮驱动下，服用膳食营养补充剂已进阶为现代 人健康管理的核心方案。在消费者决策矩阵中，产品本身与品牌背书构成购买双引擎。但不同人群对成分需 求呈现差异化特征，折射精准健康管理趋势。 三、 Omega-3 产品与应用现状 Om ...

Core Viewpoint - Sanhua Intelligent Control plans to raise HKD 8 billion through its IPO in Hong Kong, but the necessity of this fundraising is questionable due to fluctuating capacity utilization and slowing growth rates in recent years [1][2]. Group 1: IPO Details - Sanhua Intelligent Control is set to launch its IPO on the Hong Kong Stock Exchange, having secured cornerstone investment agreements with 16 well-known institutions, including Schroders and GIC [1]. - The company plans to issue 360 million H-shares, with 7% allocated for public offering in Hong Kong and 93% for international placement, along with a 15% over-allotment option [2]. - The indicative price range for the shares is HKD 21.21 to HKD 22.53, with a midpoint price of HKD 21.87 expected to yield approximately HKD 77.41 billion in net proceeds [2][3]. Group 2: Fund Utilization - Approximately 30% of the net proceeds (HKD 23.22 billion) will be allocated for ongoing global R&D and innovation to strengthen existing capabilities and achieve sustainable growth over the next three years [2][3]. - Another 30% (HKD 23.22 billion) is earmarked for expanding and constructing new factories in China, as well as enhancing production automation to improve capacity and efficiency [2][3]. - 25% of the net proceeds (HKD 19.35 billion) will be used to deepen global presence by expanding overseas capacity, while 5% (HKD 3.87 billion) will enhance digital infrastructure across various business processes [3]. Group 3: Capacity and Financial Performance - The company's capacity utilization has shown volatility, with a decline noted in the past year, recording 83.8%, 92.2%, and 91.2% from 2022 to 2024 [4]. - The capital expenditure is on the rise, but the net cash flow from operating activities is sufficient to cover these expenses [4][6]. - As of the end of Q1, the company's debt-to-asset ratio decreased significantly to 44.91% from 53% in 2022, indicating improved financial health [6]. Group 4: Revenue Growth and Challenges - Sanhua Intelligent Control is the largest manufacturer of refrigeration control components globally, with revenue growth from 121 billion to 279 billion from 2020 to 2024, but growth rates have been slowing [7][9]. - The revenue growth rates for the same period were 7.29%, 32.30%, 33.25%, 15.04%, and 13.8%, while net profit growth rates were 2.76%, 15.7%, 52.98%, 12.49%, and 6.07% [7]. - Accounts receivable have increased significantly, with a 20% growth rate in 2024, while revenue growth was only 13.8%, indicating potential issues with cash flow management [9]. Group 5: Market Position and Competition - The company holds a dominant market share of 45.5% in the global refrigeration control components market, but faces intense competition from major manufacturers [10]. - In the automotive parts sector, Sanhua's revenue grew from 75.14 billion to 113.87 billion from 2022 to 2024, with a market share of approximately 4.1% in the automotive thermal management systems [12]. - The company is also exploring opportunities in the robotics sector, planning to invest at least HKD 3.8 billion in a new R&D and production base for robotic actuators [12].

通信行业动态报告 量子计算光量子技术路线进展加速，未来大有可为 2025 年 06 月 11 日 ➢ 光量子是量子计算重要的技术路线之一，具有独特的竞争优势：量子计算以 量子比特为基本单元，利用量子叠加和干涉等原理实现并行计算，在理论上能在 特定领域实现指数级加速，因而是未来计算能力跨越式发展的重要方向。量子计 算技术路线众多，当前多种技术路线并行发展尚无收敛趋势。可分为两大类，一 是基于微观结构形成分立能级系统的"人造粒子"路线，如超导和硅半导体，二 是直接操控微观粒子的天然粒子路线，如量子阱、光量子和中性原子。其中，光 量子是重要的技术路线之一，其是基于量子叠加态和纠缠态原理，通过非线性光 学效应产生纠缠光子对，再利用线性光学元件对光子进行操控以实现量子逻辑运 算。相较于其他路线，光量子具备独特竞争优势。其支持室温工作，相干时间长， 同时光子可以实现长距离纠缠，适合构建分布式量子计算网络。并且，光量子计 算可以与现有的光纤通信基础设施兼容，不需要信号的转换就能够进行扩展。 ➢ 光量子技术路线研究热度高，产业生态正逐步形成：根据中国信通院统计， 截至 2023 年 9 月，量子计算硬件技术路线的专利申请数量 ...

高纯度 Omega-3丨 白皮书 核心摘要： 在健康中国战略全面推进的背景下，国民健康管理意识显著提升，健康需求从 "被动治疗"向"主动预防"加 速转型。随着慢性病防控与亚健康改善成为全民健康的核心议题，膳食营养补充剂已成为全民健康管理的重 要工具，其市场发展与科学认知深化同步推进。基于这一现状，本白皮书旨在深入探讨高纯度 Omega-3 在中国居民健康管理中的作用及应用现状，加强公众对其生理功效的认知，为公众提供更加专业的营养指 导。白皮书从以下五个章节展开： 一、中国居民健康管理现状 国家政策推动全民健康管理向主动预防转型，面对慢性病年轻化与全周期防护挑战，需构建监测、干预与营 养支持体系。膳食营养补充剂通过定向支持和免疫力提升，成为公众践行主动健康管理的核心工具，助力实 现从治疗到预防的跨越。 二、膳食营养补充剂市场认知及应用表现 在国民健康管理需求升级与膳食营养补充剂市场快速发展的双轮驱动下，服用膳食营养补充剂已进阶为现代 人健康管理的核心方案。在消费者决策矩阵中，产品本身与品牌背书构成购买双引擎。但不同人群对成分需 求呈现差异化特征，折射精准健康管理趋势。 三、 Omega-3 产品与应用现状 Om ...

2025年5月，艾瑞咨询从行业趋势、竞争格局、企业经营等方面对鱼油行业开展了专项研究与调 研，在研究市场上现有的鱼油产品后发现，WHC高纯鱼油脱颖而出。结合行业专家、电商数据 与行业洞察，艾瑞咨询对WHC高纯鱼油的市场地位展开了证明工作，并颁发了【WHC 高端高 纯度鱼油全国销量第一】市场地位证明书。 当前我国居民健康素养水平显著提升 我国居民健康素养在国家政策持续推动下显著提升，公众健康管理意识已从被动应对向主动预防转 变。当前健康管理需同步应对两大核心任务：一是遏制三高问题、心脑血管问题、糖尿病等慢性病 的高发态势及其年轻化趋势，二是构建覆盖全生命周期的疾病预防体系。遗传、环境与生活方式的 多维作用机制，决定了健康管理必须融合科学监测、行为干预和营养支持的综合策略。 科学服用膳食营养补充剂已成为精准营养管理的手段之一 在国民健康管理意识觉醒与膳食营养补充剂产业升级的双向驱动下，科学服用膳食营养补充剂已成 为现代人健康管理体系的重要支柱。整体来看，当前市场呈现显著的需求分层特征，不同人群的健 康管理需求各有侧重，这种差异化选择本质上反映了全民健康管理正在向个性化、精细化纵深发 展。 艾瑞咨询是艾瑞数智旗下品 ...